Source:http://linkedlifedata.com/resource/pubmed/id/12890213
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2003-7-31
|
pubmed:abstractText |
There is a known relationship between the use of immunosuppressive therapies and the development of lymphoproliferative malignancies. These lymphomas are mainly B-cell nonHodgkin's lymphomas associated with Epstein-Barr virus. Most cases concern classical immunosuppressive treatments including ciclosporin and methotrexate. A relationship between the new antitumour necrosis factor (TNF)-alpha agents and lymphoproliferative malignancies is debated. Patients with psoriasis on immunosuppressive therapies, mainly ciclosporin, are considered to have a low risk of developing lymphoid proliferation. We report a patient with erythrodermic psoriasis treated with ciclosporin and infliximab who developed a CD30+ T-cell lymphoma. This lymphoma regressed after stopping these treatments. In this case, the anti-TNF-alpha agent may have played a role in association with ciclosporin in the development of the lymphoproliferative disorder. Whereas the combination of anti-TNF-alpha therapies with methotrexate has been well studied, their combination with ciclosporin has been evaluated only in a few patients. Psoriatic patients who may require anti-TNF-alpha treatment have often been or will be treated with ciclosporin. The combination of ciclosporin and anti-TNF-alpha warrants further investigation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Dermatologic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0007-0963
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
149
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
170-3
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12890213-Antibodies, Monoclonal,
pubmed-meshheading:12890213-Cyclosporine,
pubmed-meshheading:12890213-Dermatologic Agents,
pubmed-meshheading:12890213-Drug Therapy, Combination,
pubmed-meshheading:12890213-Humans,
pubmed-meshheading:12890213-Immunosuppressive Agents,
pubmed-meshheading:12890213-Lymphoma, Large-Cell, Anaplastic,
pubmed-meshheading:12890213-Male,
pubmed-meshheading:12890213-Middle Aged,
pubmed-meshheading:12890213-Psoriasis,
pubmed-meshheading:12890213-Skin Neoplasms
|
pubmed:year |
2003
|
pubmed:articleTitle |
CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab.
|
pubmed:affiliation |
Department of Dermatology, Bichat-Claude Bernard Hospital, 46 Rue Henri-Huchard, Paris Cedex 18, France. emmanuel.mahe@bch.ap-hop-paris.fr
|
pubmed:publicationType |
Journal Article,
Review,
Case Reports
|